216 related articles for article (PubMed ID: 30888405)
1. Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases.
Borren NZ; Luther J; Colizzo FP; Garber JG; Khalili H; Ananthakrishnan AN
J Crohns Colitis; 2019 Aug; 13(8):990-995. PubMed ID: 30888405
[TBL] [Abstract][Full Text] [Related]
2. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
Colman RJ; Rubin DT
J Crohns Colitis; 2015 Apr; 9(4):312-7. PubMed ID: 25616487
[TBL] [Abstract][Full Text] [Related]
3. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
4. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
[TBL] [Abstract][Full Text] [Related]
5. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
[TBL] [Abstract][Full Text] [Related]
6. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease.
Maté-Jiménez J; Hermida C; Cantero-Perona J; Moreno-Otero R
Eur J Gastroenterol Hepatol; 2000 Nov; 12(11):1227-33. PubMed ID: 11111780
[TBL] [Abstract][Full Text] [Related]
7. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center.
Willot S; Noble A; Deslandres C
Inflamm Bowel Dis; 2011 Dec; 17(12):2521-6. PubMed ID: 21337668
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate for Inflammatory Bowel Diseases - New Developments.
Herfarth HH
Dig Dis; 2016; 34(1-2):140-6. PubMed ID: 26981630
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Safety and Mucosal Healing of Methotrexate in a Large Longitudinal Cohort of Inflammatory Bowel Disease Patients.
Rouiller-Braunschweig C; Fournier N; Pittet V; Dudler J; Michetti P
Digestion; 2017 Nov; 96(4):220-227. PubMed ID: 29065423
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate for maintaining remission in paediatric Crohn's patients with prior failure or intolerance to thiopurines: a multicenter cohort study.
Haisma SM; Lijftogt T; Kindermann A; Damen G; de Ridder L; Escher JC; Mearin ML; de Meij T; Hendriks D; George E; Hummel T; Norbruis O; van Rheenen P
J Crohns Colitis; 2015 Apr; 9(4):305-11. PubMed ID: 25656249
[TBL] [Abstract][Full Text] [Related]
12. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
van Mens LJJ; de Jong HM; Fluri I; Nurmohamed MT; van de Sande MGH; Kok M; van Kuijk AWR; Baeten D
Ann Rheum Dis; 2019 May; 78(5):610-616. PubMed ID: 30808625
[TBL] [Abstract][Full Text] [Related]
13. When to Start Immunomodulators in Inflammatory Bowel Disease?
Sharara AI
Dig Dis; 2016; 34(1-2):125-31. PubMed ID: 26982809
[TBL] [Abstract][Full Text] [Related]
14. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
15. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and Risk Factors for Symptoms of Methotrexate Intolerance in Pediatric Inflammatory Bowel Disease.
Dupont-Lucas C; Grandjean-Blanchet C; Leduc B; Tripcovici M; Larocque C; Gervais F; Jantchou P; Amre D; Deslandres C
Inflamm Bowel Dis; 2017 Feb; 23(2):298-303. PubMed ID: 28107279
[TBL] [Abstract][Full Text] [Related]
17. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
Johnson CM; Dassopoulos T
Curr Gastroenterol Rep; 2018 Sep; 20(11):53. PubMed ID: 30267281
[TBL] [Abstract][Full Text] [Related]
18. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
[TBL] [Abstract][Full Text] [Related]
20. Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis.
Dhindsa BS; Dhaliwal A; Mashiana HS; Saghir SM; Sayles H; Mubder M; Ohning G; Eichele D
Indian J Gastroenterol; 2020 Apr; 39(2):153-160. PubMed ID: 32468382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
